Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
FcRn Antibody Fragment Submitted To US FDA In January
Executive Summary
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
You may also be interested in...
Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Coronavirus Update: Inovio Looks Outside US To Continue Vaccine Development
Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19.
UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.